Skip to main content

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the JMP Securities Hematology and Oncology Summit.

JMP Securities Hematology and Oncology Summit
Fireside Chat: Tuesday, December 5, 2023 at 1:30 pm ET
Location: Virtual

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  248.15
-0.88 (-0.35%)
AAPL  260.53
+1.70 (0.66%)
AMD  255.62
+0.55 (0.22%)
BAC  54.23
+0.88 (1.66%)
GOOG  331.99
+1.41 (0.43%)
META  674.73
+12.24 (1.85%)
MSFT  406.24
+13.13 (3.34%)
NVDA  199.43
+2.92 (1.49%)
ORCL  170.85
+7.85 (4.82%)
TSLA  377.16
+12.96 (3.56%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.